

PETER DAVID EISENBERG, M.D., FACP

CURRICULUM VITAE

PERSONAL

Address: California Cancer Care, Inc.
1350 South Eliseo Drive, Suite 200
Greenbrae, California 94904-2007

Telephone: (415) 925-5000

EDUCATION

B.A. 1963-67 Biology
Franklin & Marshall College
Lancaster, Pennsylvania

M.D. 1967-72 Hahnemann Medical College
Philadelphia, Pennsylvania

GRADUATE MEDICAL EDUCATION

Internship 1972-73 Internal Medicine,
Jacksonville Hospitals Education Program
University of Florida

Residency 1973-74 Internal Medicine, Graduate Medical Education
Michigan State University
East Lansing

Fellowship 1974-76 Hematology & Oncology
Jacksonville Hospitals Education Program, University of Florida

1976-78 Hematology & Oncology, Assistant Research Physician
Cancer Research Institute, University of California, San Francisco

PROFESSIONAL ACTIVITIES

1978-present Practitioner of Hematology and Medical Oncology, Greenbrae, CA

1978 Privileges at Marin General Hospital

1983-84 Host, KCBS Radio, *Health Magazine*

1986-94 Medical Adviser, Blue Shield/Medicare

1989-93 Principal Investigator, California Healthcare Systems Community Clinical Oncology Program (CCOP)

- 1990-1999 Associate Scientist, Geraldine Brush Cancer Research Institute, Medical Research Institute of San Francisco
- 1993-1999 Principal Investigator, Sutter Health, Cancer Research Group
- 1993-1999 Medical Director, Marin Cancer Institute
- 1995-1998 Medical Advisor, Blue Cross
- 1997 - Medical Director of Medical Oncology, Doctors Medical Center; Privileges at Doctors Medical Center
- 2000- Chairman, Marin General Hospital Institutional Review Board
- 2003 Member, Joseph Simone's ASCO Alpha Quality Group
- 2003 Member, National Quality Forum's Cancer Care Quality Measures Steering Committee
- 2003 Member, NCI Committee to plan "An Idealized Design for Cancer Care"
- 2003 Member, Institute of Medicine Committee to Assess Improvements in Cancer Care in Georgia

CERTIFICATIONS AND LICENSES

- July, 1973 Diplomate, National Board of Medical Examiners
- June, 1976 California License
- June, 1976 Diplomate, American Board of Internal Medicine, Internal Medicine
- November, 1991 Diplomate, American Board of Internal Medicine, Medical Oncology

MEMBERSHIPS

- 1966-1967 Member, Senior Honor Society, Franklin and Marshall College
- 1971-1972 President Student Body, Hahnemann Medical College
- 1974-1975 Fellow, American Cancer Society
- 1978-1999 Principal Investigator, National Surgical Adjuvant Breast and Bowel Project
- 1979-1981 Member, Board of Directors, American Heart Association, Marin Chapter
- 1979-1981 Member, Board of Directors, American Cancer Society, Marin Unit
- 1988-1990 Member, Board of Directors, American Cancer Society, Marin Unit

1981-1991	Member, Board of Directors, Marin General Hospital District
1983-1985	Chairman, Board of Directors, Marin General Hospital District
1983-1987	Chairman, Clinical Research Committee, Marin Cancer Council
1983-1987	Member, Board of Directors, San Francisco Regional Cancer Foundation
1984-1989	Principal Investigator, Northern California Oncology Group
1986-present	Fellow, American College of Physicians
1987-1989	Member, Board of Directors, Hospice of Marin
1987-1989	Chairman, Board of Directors, Marin General Hospital District
1990-1993	Founder and President, Association of Northern California Oncologists
1993-1996	Member, Executive Committee, National Surgical Adjuvant Breast and Bowel Project
1994-1998	Member, Physicians Relations Committee, Blue Cross of California
1995-2000	Member, Health Services Research Committee, ASCO.
2000-	Member, Clinical Practice, ASCO.
2002-	Member, Ethics Committee, ASCO
2003-	Member, Health Services Research Committee, ASCO.

RESEARCH EXPERIENCE

1978 – present Ongoing Clinical Phase I, II, III, and IV Pharmaceutical Oncology Trial experience as the Principal Investigator; to date, involved in over 500 Oncology trials

PUBLICATIONS

Eisenberg, P.D., Aster, R.H., and Abramson, N.: "Post-Transfusion Purpura: New Aspects of Diagnosis and Therapy." (Abstract) American Society of Hematology. Blood, (1974).

Abramson, N., **Eisenberg, P.D.**, and Aster, R.H.: "Post-Transfusion Purpura: Immunologic Aspects and Therapy." New England Journal of Medicine. 291:1163-1166 (November 28, 1974).

Eisenberg, P.D. and Abramson, N.: "Post -Transfusion Purpura Revisited." (letter) New England Journal of Medicine. 296:515-516 (March 3, 1977).

Mohandas, N., Clark, M.R., Wyatt, J.F., **Eisenberg, P.D.**, and Shohet, S.B.: "Erythropoietic Stress, Macrocytosis and Hemoglobin Switching in HbAA Sheep." Blood. 55:757-761 (May, 1980).

Wickerham, L., Fisher, B., Cronin, W., Stollbach, L., Abramson, N., Bowman, D., Deckers, P.J., **Eisenberg, P.D.**, Foster, R., Glass, A., Kay, S., Kyle, A., Prager, D. and Pritchard, K.: "The Efficacy of Bone Scanning in the Follow-Up of Patients with Operable Breast Cancer." Breast Cancer Research and Treatment. 4:303-307 (1984).

Valone, F.H., Friedman, M.A., Wittlinger, P.F., Drakes, T., **Eisenberg, P.D.**, Brown, B.W., Malec, M., Hannigan, J.: "Treatment of Patients with Advanced Colorectal Carcinomas with 5-FU Alone, High Dose Leucovorin Plus 5-FU or Sequential Methotrexate, 5-FU, Leucovorin: A Randomized Trial of the Northern California Oncology Group." J Clin Oncol.7:1427-1436 (October, 1989)

Carlson, R.W., Borrison, R.A., Sher, H.B., **Eisenberg, P.D.**, Mowry, P.A., Wolin, E.M.: "A multiinstitutional evaluation of the analgesic efficacy and safety of ketorolac tromethamine, acetaminophen plus codeine, and placebo in cancer pain." Pharmacotherapy 1990;10(3):211-6.

Valone, F.H., Wittlinger, P.S., Flam M.S., Drakes, T., **Eisenberg, P.D.**, Hannigan, J.: "A northern California Oncology Group randomized trial of single agent 5-FU vs. high-dose folinic acid + 5-FU vs. methotrexate + 5-FU + folinic acid in patients with disseminated measurable large bowel cancer." Adv Exp Med Biol 1988:244:193-9.

Plezia, P., Modiano, M., Alberts, D., Bertoli, L., Yielding A., **Eisenberg, P.**, Khojasteh A., Gandara D., Heck, K., Hahne, W.: "A double-blind, randomized, parallel study of two doses of intravenous (IV) MDL 73, 147EF in patients (pts) receiving high dose Cisplatin (CDDP)-Containing Chemotherapy (CT)." Proceedings of ASCO March 1992:V. Vol. 11: p407.

LeVeque, Francis G, Parzuchowski, Jeanne B., Farinacci, George C., Redding, Spencer W., Rodu, Brad, Johnson, Jonas T., Ferretti, Gerald A., **Eisenberg, Peter D.**, and Michael B. Zimmer.: "Clinical Evaluation of MGI 209, an anesthetic film-forming agent for relief from painful oral ulcers associated with chemotherapy." Journal of Clinical Oncology, Vol 10, No. 12 (December), 1992:pp1963-1968.

Poplin, Elizabeth, Fleming, Tom, MacDonald, John S., **Eisenberg, Peter**, Fisher, Richard I., and Conrad, Marcel E.: "Amonafide Treatment of Refractory Esophageal Cancer" Investigational New Drugs, Vol 11:pp47-51, 1993.

Burris, H., Vogel, C., Schwarz, M., Spencer, S., Lentz, M., Abramson, N., **Eisenberg, P.**, Fleming, G, George, S., Sher, H., Lopez, L., Baughman, J., and Korey A. "A Phase I/II Multi-center Clinical Trial of the Cisplatin Therapeutic Implant (MPI 5010) for Treatment of Solid Tumors." (Abstract #1369) ASCO Proceedings, Vol 13:pp402 1994.

Grunberg, S., Andrews, P., Dilly, S., Perez, A. & Gandara, D., Palmer, R., **Eisenberg, P.** "Further profiles of Granisetron (Kytril): Effect on Quality of Life and Pharmacoeconomics" Seminars in Oncology, June 1994: pp26-28.

E. Rubenstein, L. Kalman, J. Hainsworth, P. Plezia, M. Modiano, **P. Eisenberg, P.** Hesketh, K. Frieze, J. Whitmore, M. Cramer, W. Hahne. "Dose Response Trial Across 4 Oral Doses of Dolasetron (D) for Emesis Prevention After Moderately Emetogenic Chemotherapy (CT)." (Abstract #1737) ASCO Proceedings, Vol 14:pp527 1995.

Buzdar, A.U., Plourde, S.E., Jones, S.E., Vogel, C.L., Wolters, J.M., **Eisenberg, P.D.** and the N American Arimidex Study Group: "Randomized phase III study of the new selective aromatase inhibitor arimidex (A) (ZD1033) versus megestrol acetate (MA) in the treatment of postmenopausal women with advanced breast cancer." (Abstract #104) 4th Nottingham International Breast Cancer Conference Breast, Vol 4 (3):pp256-257 1995.

Ravdin PM, Burris HA III, Cook G, **Eisenberg P**, Kane M, Bierman WA, Mortimer J, Genevois E, Bellet RE. "Phase II Trial of Docetaxel in Advanced Anthracycline-resistant or Anthracenedione-resistant Breast Cancer." Journal of Clinical Oncology, Vol. 13 No. 12 (December), 1995: pp2879-2885.

Ettinger DS, **Eisenberg P**, Fitts D, Friedman C, Wilson-Lynch K, Yocom K. "A Double-Blind Comparison of the Efficacy of Two Dose Regimens of Oral Granisetron in Preventing Acute Emesis in Patients Receiving Moderately Emetogenic Chemotherapy." Cancer, Vol. 78, No. 1 (July) 1996: pp 144-151.

Gradishar WJ, Loh K, Erban J, Vogel C, Grabelsky S, Cohen R, Limentani S, Woodard W, Dobbs T, **Eisenberg P**, Swain S. "Preliminary results from a phase II study of (Taxotere® [T]) docetaxel as primary chemotherapy (PCT) followed by doxorubicin (A) and cyclophosphamide (C) in stage III breast cancer." Proceedings of ASCO, Vol. 16, 1997: p 171a.

Jones S, Vogel C, Arkhipov A, Fehrenbacher L, **Eisenberg P**, Cooper B, Honig S, Polli A, Whaley F, di Salle E, Tiffany J, Consonni A, and Miller L. "Multicenter, Phase II Trial of Exemestane as Third-Line Hormonal Therapy of Postmenopausal Women With Metastatic Breast Cancer." Journal of Clinical Oncology, Vol. 17, No. 11 (November), 1999: pp 3418-3425.

Moore M, Hamm J, **Eisenberg P**, Dagenais M, Hagan Kate Ackenheil, Fields A, Greenberg B, Schwartz B, Ottaway J, Zee B, Seymour L; NCIC Clin Trials Group, Kingston, Canada; Bayer Inc., Toronto, Canada. "A Comparison Between Gemcitabine (GEM) and the Matrix Metalloproteinase (MMP) Inhibitor BAY 12-9566 (9566) in Patients (Pts) with Advanced Pancreatic Cancer." Proceedings of ASCO, Vol. 19, May 20-23, 2000: p 240a.

Rizvi N, **Eisenberg P**, Reich S; Lombardi Cancer Center Washington, D.C.; Marin Oncology Associates, Greenbrae, CA; Ligand Pharmaceuticals, San Diego, CA. "Placebo-Controlled Trial of Bexarotene (Targretin, LGD1069), a Retinoid X Receptor (RXR) Agonist, as Maintenance Therapy for Patients Treated with Chemotherapy for Advanced Non-Small Cell Lung Cancer (NSCLC): AL1069-20 Study Group Trial." Proceedings of ASCO, Vol. 19, May 20-23, 2000: p 535a.

Lonning P, Bajetta E, Murray R, Tubiana-Hulin M, **Eisenberg P**, Mickiewicz E, Celio L, Pitt P, Mita M, Aaronson N, Fowst C, Arkhipov A, di Salle E, Polli A, Massimini G. "Activity of Exemestane in Metastatic Breast Cancer After Failure of Nonsteroidal Aromatase Inhibitors: A Phase II Trial." Journal of Clinical Oncology, Vol. 18, No. 11 (June), 2000: pp 2234-2244.

Schapiro L, **Eisenberg P**, MacDonald N, Mumber M, and Loprinzi C. "The Art of Oncology: When the Tumor is Not the Target. A Revisitation of 'Doc, How Much Time Do I Have?' " Journal of Clinical Oncology, Vol. 18, No. 13 (July), 2000: pp 2640-2643.

Rizvi N, Hawkins M, **Eisenberg P**, Yocum R, Reich S and the Ligand L1069-20 Working Group. "Placebo-Controlled Trial of Bexarotene, a Retinoid X Receptor Agonist, as Maintenance Therapy for Patients Treated with Chemotherapy for Advanced Non-Small Cell Lung Cancer." Clinical Lung Cancer, Vol. 2, No. 3, February 2001: pp 210-215.

Buzdar A, Hayes D, El-Khoudary A, Yan S, Lønning P, Lichinitser M, Gopal R, Falkson G, Pritchard K, Lipton A, Wolter K, Lee A, Fly K, Chew R, Alderdice M, Burke K, and Eisenberg P. "Phase III randomized trial of droloxifene and tamoxifen as first-line endocrine treatment of ER/PgR-positive advanced breast cancer." Breast Cancer Research and Treatment, Vol 73, 2002: pp161-175.

N.A. Rizvi, W. Miller, H Frank, D. Small, J. Aisner, **P. Eisenberg**, G.R. Blumenschein, F. Khuri. "Phase I/II safety evaluation of bexarotene in combination with carboplatin and paclitaxel in patients with chemotherapy-naïve advanced non-small cell lung cancer. (NSCLC.)" Proceedings of ASCO, Vol. 19, May 18-21, 2002: p 1334.

Douillard J-Y, Hoff P, Skillings J, **Eisenberg P**, Davidson N, Harper P, Vincent M, Lembersky B, Thompson S, Maniero A, and Benner S. "Multicenter Phase III Study of Uracil/Tegafur and Oral Leucovorin Versus Fluorouracil and Leucovorin in Patients With Previously Untreated Metastatic Colorectal Cancer." Journal of Clinical Oncology, Vol 20, No 17 (September 1), 2002: pp 3605-3616.

Lichtman S, Etcubanas E, Budman D, Eisenberg P, Zervos G, D'Amico P, O'Mara V, Musgrave K, Cascella P, Melikian A, Hinderling P, Ferrer J, and Williams G. "The Pharmacokinetics and Pharmacodynamics of Fludarabine Phosphate in Patients with Renal Impairment: A Prospective Dose Adjustment Study." Cancer Investigation, vol. 20, No 7 & 8, 2002: pp 904-913.

Cohen L, De Moor C, **Eisenberg P**, Grunberg SM, Kim YJ, and Rubenstein EB. "Delayed chemotherapy-induced nausea and vomiting (CINV) remains a problem and significantly interferes with daily function (DF) in pts receiving emetogenic chemotherapy (CT) in the United States." Proceedings of ASCO, Vol. 22, May 18-June 3, 2003: p 739.

Eisenberg PD, Rubenstein EB, Cohen L, De Moor C, Kim YJ, and Grunberg SM. "Perceptions and satisfaction (S) of oncologists (MDs) and oncology nurses (RNs) of antiemetic therapy (AET) for chemotherapy-induced nausea and vomiting (CINV) vs. patient experiences after emetogenic chemotherapy (CT) in the US." Proceedings of ASCO, Vol. 22, May 18-June 3, 2003: p 740.

Demoor C, Cohen L, **Eisenberg PD**, Grunberg SM, Kim YJ, and Rubenstein EB. "Oncologists' compliance with antiemetic guidelines (AEG) and outcomes of patients (pts) receiving emetogenic chemotherapy (CT)." Proceedings of ASCO, Vol. 22, May 18-June 3, 2003: p 727.

Rubenstein EB, Gralla RJ, **Eisenberg P**, Sleeboom, Vtoraya O, Macciocchi A, Olivares G, and Berry D. "Palonosetron (PALO) compared with ondansetron (OND) or dolasetron (DOL) for Prevention of Acute & Delayed Chemotherapy-Induced Nausea and Vomiting (CINV): Combined Results of Two Phase III Trials." Proceedings of ASCO, Vol. 22, May 18-June 3, 2003: p 727.

Moore MJ, Hamm, J. Dancy J, **Eisenberg PD**, Dagenais M, Fields A, Hagan K, Greenberg B, Colwell B, Zee B, Tu D, Ottaway J, Humphrey R, and L. Seymour. "Comparison of Gemcitabine versus the Matrix Metalloproteinase Inhibitor BAY 12-9566 in Patients With Advanced or Metastatic Adenocarcinoma of the Pancreas: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group." Journal of Clinical Oncology, vol. 21, No 17, (September 1), 2003: pp 3296-3302.

Cohen L, de Moor C, **Eisenberg PD**, Kim YJ, Ming, E, Kanesan K, and Rubenstein EB. "Expectations of Side Effects are Associated with Health Status and Fatigue in Patients receiving Chemotherapy (CT)." Proceedings of MASCC, Vol. 11, June 18-21, 2003: p 403.

de Moor C, Cohen L, **Eisenberg PD**, Kim YJ, Ming, E, and Rubenstein EB. "Patterns if Chemotherapy Induced Nausea and Vomiting (CINV) in Patients (PTS) Receiving Chemotherapy." Proceedings of MASCC, Vol. 11, June 18-21, 2003: p 395.

Meyers CA, Smith JA, Bezjak A, Mehta MP, Liebmann J, Illidge T, Kunkler I, Caudrelier JM, Eisenberg PD, Meerwaldt J, Siemers R, Carrie C, Gaspar LE, Curran W, Phan SC, Miller RA, and Renschler MF. "Neurocognitive Function and Progression in Patients With Brain Metastases Treated With Whole-Brain Radiation and Motexafin Gadolinium: Results of a Randomized Phase III Trial." Journal of Clinical Oncology, vol. 22, No 1, (January 1), 2004: pp 157-165.

RECENT ADDRESSES AND PRESENTATIONS

ASCO 2001: Education Session Discussant, “Evidence-Based Oncology Meets Clinical Experience: Challenges and Opportunities.”

ASCO 2001: Educational Symposium Chair, “Using Quality to Survive Managed Care.”

ASCO 2002: Special Session Discussant, “Issues in the Access if Promising New Cancer Agents.”



CALIFORNIA
CANCER
CARE